Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target hoisted by Citigroup from $125.00 to $127.00 in a research note issued to investors on Tuesday, Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed an […]
HC Wainwright reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $180.00 target price on the stock. Several other equities research analysts have also issued reports on AXSM. Citigroup started coverage on Axsome Therapeutics in a […]
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price decreased by equities researchers at Mizuho from $112.00 to $108.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Mizuho’s price objective indicates a potential upside of 30.20% from the company’s previous close. Other […]
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price lowered by investment analysts at Mizuho from $112.00 to $108.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Mizuho’s target price points to a potential upside of 30.92% from the company’s current price. Other […]
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective dropped by equities researchers at Royal Bank of Canada from $126.00 to $123.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank of Canada’s price target points to a potential upside of 46.50% […]